New drug targets tough cancers with KRas G12V mutation
NCT ID NCT07650357
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safety, find the best dose, and see if the drug shows any sign of shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CLSP-5282 (an experimental drug given by IV infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for people with certain hard-to-treat cancers that have a specific genetic mutation.
- What could go wrong
- This is a very early (Phase 1) trial with only 140 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke Cancer Institute
Durham, North Carolina, 27701, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75230, United States
-
Sarah Cannon Research Institute (SCRI) Oncology Partners
Nashville, Tennessee, 37203, United States
-
Thomas Jefferson University, Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can your own immune cells beat advanced cancer?
- Can we predict chemo brain before it happens?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Your gut bacteria might reveal hidden cancer risk